Cargando…

Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members

INTRODUCTION: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects nearly 70% of cancer patients after chemotherapy, causing sensory, motor, autonomic dysfunction, and neuropathic pain. The Desirability of Outcome Ranking (DOOR) framework is proposed as a better way to assess preventive or t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardo, Salvatore, Varrassi, Giustino, Scartozzi, Mario, Pace, Maria Caterina, Schweiger, Vittorio, Tamburin, Stefano, Musu, Mario, Finco, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542526/
https://www.ncbi.nlm.nih.gov/pubmed/37790191
http://dx.doi.org/10.2147/JPR.S414389
_version_ 1785114110843682816
author Sardo, Salvatore
Varrassi, Giustino
Scartozzi, Mario
Pace, Maria Caterina
Schweiger, Vittorio
Tamburin, Stefano
Musu, Mario
Finco, Gabriele
author_facet Sardo, Salvatore
Varrassi, Giustino
Scartozzi, Mario
Pace, Maria Caterina
Schweiger, Vittorio
Tamburin, Stefano
Musu, Mario
Finco, Gabriele
author_sort Sardo, Salvatore
collection PubMed
description INTRODUCTION: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects nearly 70% of cancer patients after chemotherapy, causing sensory, motor, autonomic dysfunction, and neuropathic pain. The Desirability of Outcome Ranking (DOOR) framework is proposed as a better way to assess preventive or therapeutic interventions for CIPN. METHODS: A survey was conducted among Italian healthcare professionals and researchers affiliated to the Italian Chapter of the International Association for the Study of Pain (AISD) to identify the most important outcomes in clinical management and research. RESULTS: Among the 73 respondents, 61 qualified for the survey, with an overall response rate of 1.2%. The vast majority were physicians (77%), most of whom were anesthesiologists (47.5%). The results showed that pain, survival, sensory impairment, motor impairment, and quality of life were consistently ranked as the most important outcomes, but there was significant disagreement in the outcomes relative ranking, making it difficult to develop a DOOR algorithm. The study also revealed that clinicians commonly use structured interviews to evaluate patients with CIPN, and the most prescribed drugs or supplements were palmitoylethanolamide, pregabalin, gabapentin and alpha lipoic acid as preventive agents and pregabalin, palmitoylethanolamide, duloxetine, gabapentin, and amitriptyline as therapeutic agents. However, many of these drugs have not been clinically proven to be effective for CIPN. DISCUSSION: This study suggests that the implementation of a DOOR framework for CIPN using healthcare professionals is more difficult than expected, given the significant disagreement in our respondents’ ranking of outcomes. Our work provides interesting topics for future research in CIPN, but its limitations include a small sample size, a low response rate, and a possible selection bias.
format Online
Article
Text
id pubmed-10542526
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105425262023-10-03 Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members Sardo, Salvatore Varrassi, Giustino Scartozzi, Mario Pace, Maria Caterina Schweiger, Vittorio Tamburin, Stefano Musu, Mario Finco, Gabriele J Pain Res Original Research INTRODUCTION: Chemotherapy-induced peripheral neurotoxicity (CIPN) affects nearly 70% of cancer patients after chemotherapy, causing sensory, motor, autonomic dysfunction, and neuropathic pain. The Desirability of Outcome Ranking (DOOR) framework is proposed as a better way to assess preventive or therapeutic interventions for CIPN. METHODS: A survey was conducted among Italian healthcare professionals and researchers affiliated to the Italian Chapter of the International Association for the Study of Pain (AISD) to identify the most important outcomes in clinical management and research. RESULTS: Among the 73 respondents, 61 qualified for the survey, with an overall response rate of 1.2%. The vast majority were physicians (77%), most of whom were anesthesiologists (47.5%). The results showed that pain, survival, sensory impairment, motor impairment, and quality of life were consistently ranked as the most important outcomes, but there was significant disagreement in the outcomes relative ranking, making it difficult to develop a DOOR algorithm. The study also revealed that clinicians commonly use structured interviews to evaluate patients with CIPN, and the most prescribed drugs or supplements were palmitoylethanolamide, pregabalin, gabapentin and alpha lipoic acid as preventive agents and pregabalin, palmitoylethanolamide, duloxetine, gabapentin, and amitriptyline as therapeutic agents. However, many of these drugs have not been clinically proven to be effective for CIPN. DISCUSSION: This study suggests that the implementation of a DOOR framework for CIPN using healthcare professionals is more difficult than expected, given the significant disagreement in our respondents’ ranking of outcomes. Our work provides interesting topics for future research in CIPN, but its limitations include a small sample size, a low response rate, and a possible selection bias. Dove 2023-09-25 /pmc/articles/PMC10542526/ /pubmed/37790191 http://dx.doi.org/10.2147/JPR.S414389 Text en © 2023 Sardo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sardo, Salvatore
Varrassi, Giustino
Scartozzi, Mario
Pace, Maria Caterina
Schweiger, Vittorio
Tamburin, Stefano
Musu, Mario
Finco, Gabriele
Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title_full Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title_fullStr Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title_full_unstemmed Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title_short Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
title_sort exploring outcome priorities and real-life management of chemotherapy-induced peripheral neurotoxicity: a survey of the italian association for the study of pain members
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542526/
https://www.ncbi.nlm.nih.gov/pubmed/37790191
http://dx.doi.org/10.2147/JPR.S414389
work_keys_str_mv AT sardosalvatore exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT varrassigiustino exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT scartozzimario exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT pacemariacaterina exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT schweigervittorio exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT tamburinstefano exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT musumario exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers
AT fincogabriele exploringoutcomeprioritiesandreallifemanagementofchemotherapyinducedperipheralneurotoxicityasurveyoftheitalianassociationforthestudyofpainmembers